NCT00310154已完成1 期
ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- To determine the feasability of daily ZD1839 delivered with concurrent 3-dimensional planned thoracic radiation
研究概览
简要总结
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving gefitinib together with docetaxel and radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when given together with gefitinib and radiation therapy in treating patients with stage III non-small cell lung cancer.
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose of docetaxel that can be safely delivered in combination with gefitinib and a definitive course of 3-D planned thoracic radiotherapy in patients with stage III non-small cell lung cancer.
OUTLINE: This is a dose-escalation study of docetaxel.
- Chemoradiotherapy: Patients receive concurrent chemoradiotherapy comprising docetaxel IV over 30 minutes on day 1 and thoracic radiotherapy once daily on days 1-5 in weeks 1-7 in the absence of disease progression or unacceptable toxicity.
- Consolidation chemotherapy: Beginning 2 weeks after the completion of chemoradiotherapy, patients receive consolidation chemotherapy comprising docetaxel IV over 60 minutes on days 1 and 22.
- Gefitinib therapy: Patients also receive oral gefitinib once daily beginning at the start of chemoradiotherapy and continuing for up to 1 year* in the absence of disease progression.
NOTE: *Patients continue to receive gefitinib during the 2-week rest period between chemoradiotherapy and consolidation chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following:
- •Squamous cell carcinoma
- •Adenocarcinoma (including bronchoalveolar cell)
- •Large cell anaplastic carcinoma (including giant and clear cell carcinomas)
- •Stage IIIA/B disease
- •Unresectable disease
- •Tumors adjacent to a vertebral body allowed
- •No demonstrable bone invasion
- •All gross disease must be able to be encompassed in the radiation boost field in accordance with the homogeneity criteria
- •Contralateral mediastinal disease (N3) allowed if all gross disease can be encompassed in the radiation boost field in accordance with the homogeneity criteria
- •No scalene, supraclavicular, or contralateral hilar node involvement
- •Pleural effusion allowed if it is transudate, cytologically negative, and non-bloody AND tumor can be encompassed within a reasonable field of radiotherapy
- •No exudative, bloody, or cytologically malignant effusions
- •Pleural effusion seen on chest CT scan but not on chest x-ray and too small to tap allowed
- •Measurable disease, defined as lesions that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
- •No nonmeasurable disease, including any of the following:
- •Bone lesions
- •Leptomeningeal disease
- •Pleural/pericardial effusion
- •Abdominal masses that are not confirmed and followed by imaging techniques
- •Cystic lesions
- •Tumor lesions situated in a previously irradiated area
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-1
- •Granulocyte count ≥ 1,500/mm^3
- •Hemoglobin > 8.0 g/dL
- •Platelet count ≥ 100,000/mm^3
- •Bilirubin < 1.5 mg/dL
- •Creatinine < 1.5 times upper limit of normal (ULN)
- •Meets 1 of the following criteria:
- •AST and ALT < 2 times ULN
- •AST and ALT ≤ 2.5 times ULN AND alkaline phosphatase (AP) normal
- •AST and ALT normal AND AP ≤ 4 times ULN
- •FEV_1 ≥ 1.2 L
- •No other currently active malignancy except nonmelanoma skin cancers
- •Patients are not considered to have another currently active malignancy if they have completed therapy for the other malignancy and are considered by their physician to be at < 30% risk of relapse (i.e., after treatment for early-stage prostate cancer)
- •Not pregnant or nursing
- •Fertile patients must use effective contraception during and for 3 months after completing treatment
- •No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
- •No known severe hypersensitivity to gefitinib or any of the excipients of this product
- •No evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
- •No evidence of any other significant clinical disorder or laboratory finding that would limit compliance with study requirements
- •No evidence of clinically active interstitial lung disease (asymptomatic, chronic stable radiographic changes allowed)
- •No peripheral neuropathy ≥ grade 1
- •PRIOR CONCURRENT THERAPY:
- •At least 2 weeks since prior formal exploratory thoracotomy
- •No prior chemotherapy or radiotherapy for NSCLC
- •No prior epidermal growth factor-targeting drugs (i.e., gefitinib, erlotinib, or cetuximab)
- •No other investigational agent within 30 days of study entry
- 另有 5 项未显示
排除标准
- 未提供
结局指标
主要结局
To determine the feasability of daily ZD1839 delivered with concurrent 3-dimensional planned thoracic radiation
时间窗: baseline to 2 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00098462Jonsson Comprehensive Cancer Center
已完成
1 期
Gefitinib and Docetaxel in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00084786Memorial Sloan Kettering Cancer Center
已完成
2 期
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction CancerEsophageal CancerNCT00268346Case Comprehensive Cancer Center58
已完成
2 期
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyHead and Neck CancerNCT00095836Massachusetts General Hospital27
已完成
2 期
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerLung CancerNCT00217698Swiss Cancer Institute63